Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

GenScript Awarded $10 Million in Trade Secret Case Against GeneWiz

GlobeNewswire December 9, 2014

Kane Biotech Announces Closing of Private Placement Offering

Marketwired December 9, 2014

Conducting Vital Pathology Research: Easier on a Surface Pro 3

Marketwired December 9, 2014

Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014

Marketwired December 9, 2014

Aptose Biosciences Presents APTO-253 Preclinical Data at 56th American Society of Hematology Annual Meeting

Canada NewsWire December 9, 2014

Organovo Holdings, Inc.'s Presentations Now Available for On-Demand Viewing at VirtualInvestorConferences.com

Canada NewsWire December 9, 2014

Dr. Carolyn Compton and Caren Mason Join HealthTell's Board of Directors

PR Newswire December 9, 2014

Equinix Sees Uptick in Globally Deployed Financial Services Customers Spanning Multiple Asset Classes

PR Newswire December 9, 2014

ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia

Business Wire December 9, 2014

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial

Business Wire December 9, 2014

Cancer Genetics, Inc. to Receive $530,000 Through New Jersey Technology Business Tax Program

GlobeNewswire December 9, 2014

Research and Markets: Hairy Cell Leukemia - Pipeline Review, H2 2014

Business Wire December 9, 2014

Actinium's Scientific Advisory Board Endorses and Supports the Iomab-B Phase 3 Clinical Trial Development Program

Marketwired December 9, 2014

Angiochem Publishes Data On ANG4043, A Brain-Penetrant Anti-HER2 Monoclonal Antibody for Treatment of Brain Metastases

Business Wire December 9, 2014

Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting

Business Wire December 9, 2014

Ignyta Receives Approval of Nonproprietary Name Entrectinib for Lead Product Candidate, RXDX-101

Business Wire December 9, 2014

A New Era Comes When Diabetes Can Be Treated Basically Using Cells of Pancreas

Business Wire December 9, 2014

New Clinical Data Supports the Use of FoundationOne® Heme to Enable Informed Treatment Decisions in a Wide Range of Hematologic Malignancies

Business Wire December 9, 2014

eBioscience, an Affymetrix Business, Launches the First Assay to Detect RNA and Protein Simultaneously in Millions of Single Cells

Business Wire December 9, 2014

Arcturus Therapeutics Announces the Appointment of Michael R. Hodges, M.D. to the Scientific Advisory Board

PR Newswire December 9, 2014